
UBS ETF SICAV - UBS ETF - MSCI United Kingdom UCITS ETF -(hedged to USD) A-dis- Distribution
UBS ETF SICAV - UBS ETF - MSCI United Kingdom UCITS ETF -(hedged to USD) A-dis- Distribution (CH:UKUSDD) Price & Chart
CH:UKUSDD ETF Chart & Stats
- Day’s Range
- $6.96 - $6.96
- 52-Week Range
- $6.37 - $7.43
- Previous Close
- $7.02
- Volume
- 1,100
- Average Volume (3M)
- 12.66K
- AUM
- 41.08M
- NAV
- 6.99
- Expense Ratio
- 0.23%
- Holdings Count
- 66
- Beta
- 0.64
- Inception Date
- Nov 15, 2023
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 2,490,506
- Standard Deviation
- N/A
ETF Overview
UBS ETF SICAV - UBS ETF - MSCI United Kingdom UCITS ETF -(hedged to USD) A-dis- Distribution
UBS ETF SICAV - UBS ETF - MSCI United Kingdom UCITS ETF (hedged to USD) A-dis (ticker CH:UKUSDD) is a Luxembourg-domiciled, UCITS-compliant, index-tracking ETF that provides broad, passive exposure to the UK equity market by seeking to replicate the performance, before fees, of the MSCI United Kingdom Index. Designed as a Size & Style — Total Market, broad-based solution, the fund offers diversified coverage across sectors and investment styles representative of the UK market, making it suitable as a core holding for investors seeking market-wide UK equity exposure. The share class is hedged to USD, which aims to neutralize the effect of GBP/USD currency swings for dollar-based investors, reducing currency-driven volatility (while also removing potential currency upside). As an A-distributing share class, the ETF pays out income to investors, supporting income-focused strategies as well as total-return core allocations. Its passive, index-based approach offers a cost-efficient, transparent way to gain UK market exposure, ideal for investors seeking diversification, income, and minimized currency risk within a single, tradable instrument.
- Asset Class
- Equity
- Region
- Europe
- Issuer
- UBS
- Index Tracked
- MSCI United Kingdom 100% hedged to USD Index
- Ticker Symbol
- CH:UKUSDD
CH:UKUSDD ETF News


AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s GRACE-DE study, officially titled “Prospective, Observational, Multicenter, and Multicohort Study of Patients With Gastric Cancer Initiating




CH:UKUSDD ETF FAQ
What was CH:UKUSDD’s price range in the past 12 months?
What is the AUM of CH:UKUSDD?
Is CH:UKUSDD overvalued?
How many shares outstanding does CH:UKUSDD have?
CH:UKUSDD ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| HSBAHsbc Holdings Plc (UK) | 9.65% |
| SHELShell plc (UK) | 9.05% |
| AZNAstraZeneca plc | 8.88% |
| RRRolls-Royce Holdings | 4.71% |
| ULVRUnilever Plc (UK) | 4.54% |
| BATSBritish American Tobacco (UK) | 3.85% |
| BPBP p.l.c. | 3.79% |
| GSKGlaxoSmithKline plc (UK) | 3.22% |
| RIORio Tinto (LSE:RIO) | 2.75% |
| NGNational Grid (Uk) | 2.66% |
| Total | 53.09% |









